Drug Trial Radar · NCT02708004
Clinical Study to Assess Body Fluid Homeostasis After Administration of ACT-132577 in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Nov 29, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Jun 1, 2016
Primary completion
Dec 1, 2016
Study completion Dec 1, 2016
Sponsor
- Lead sponsor
- Idorsia Pharmaceuticals Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 15, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Other
- Who can join
- Male only, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This clinical study will be conducted to evaluate the effect of ACT-132577 on fluid homeostasis in healthy subjects.
Conditions
- Healthy Subjects
Interventions
AprocitentanDrug
Formulated in capsules in 2 different strengths; 2 capsules per day
PlaceboOther
Matching active drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Body weightTime frame: from Day 1 to Day 9
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Investigator Site Lausanne
Lausanne, Switzerland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.